Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nagel, Amy
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	Recruiting	3	800	Europe, US, RoW	Remibrutinib, LOU064, Teriflunomide	Novartis Pharmaceuticals, Novartis Pharma AG	Relapsing Multiple Sclerosis	04/26	10/30
REGENERATE-PD, NCT06285643: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease	Recruiting	2	87	US	AAV2-GDNF Gene therapy, Biological, Control Surgery	AskBio Inc, Bayer	Parkinson Disease	11/27	11/27
Russell, Nijah
REGENERATE-PD, NCT06285643: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease	Recruiting	2	87	US	AAV2-GDNF Gene therapy, Biological, Control Surgery	AskBio Inc, Bayer	Parkinson Disease	11/27	11/27